Trial
NCT00694291
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
Bayer
Condition
Prostate Cancer
Intervention
Sorafenib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-06